Investor Presentaiton

Investor presentation ADA 2019 OzempicⓇ now launched in 21 countries and continues to gain market shares in the USA Weekly NBRX share 60% 50% 40% 30% 20% 10% 0% Jan 2018 Slide 4 USA GLP-1 NBRx market share NN GLP-1 VictozaⓇ exenatide - - albiglutide USA GLP-1 volume market share OzempicⓇ dulaglutide NN GLP-1 Monthly TRX share 60% VictozaⓇ OzempicⓇ dulaglutide exenatide albiglutide 50.6% 50% 45.9% 39.7% 40% 44.5% 31.2% 30% 31.3% 20% 13.2% 19.4% 10% 9.6% 9.7% 0% May 2019 Feb 2017 May 2019 Source: NBRX-IQVIA LRX Weekly, week ending 19 May 2019 NBRX: New-to-brand prescriptions Source: IQVIA monthly xponent, Apr 2019, weekly xponent for May, week ending 19 May 2019

View entire presentation